Your browser doesn't support javascript.
loading
Statistics of Rare Events.
Proschan, Michael A; Kherabi, Yousra.
Afiliação
  • Proschan MA; Clinical Trials Research Section, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD.
  • Kherabi Y; Clinical Trials Research Section, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD.
NEJM Evid ; 3(1): EVIDe2300303, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38320520
ABSTRACT
Rare events can sometime arise in clinical development of treatments. For example, CYPIDES was a single-arm study of the CYP11A1 inhibitor ODM-208 to treat metastatic prostate cancer.1 Preclinical testing of the compound identified elevated thyroid-stimulating hormone (TSH) and bilirubin in rats and dogs. Unusual findings in preclinical testing focus attention and magnify evidence if similar results occur in humans. By analogy, imagine a murder trial in which the only evidence against the defendant arose from a database search of DNA matching the partial profile found at the crime scene. Multiple people could match, so without other evidence, the perpetrator could be any of them.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Hipertireoidismo Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Hipertireoidismo Idioma: En Ano de publicação: 2024 Tipo de documento: Article